Accessibility Menu
Nanobiotix logo

Nanobiotix(NASDAQ) NBTX

Market Cap$1.96BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)+128%
5 Year+206%
1 Year+433%
1 Month+1%
$39.54
+2.12%
+0.82Today
After hours$39.62+$0.08 (+0.20%)
Nanobiotix last closing stock price
MetricPriceDate
Last closeUSD 39.442026-08-12
Nanobiotix stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-0.58%USD 39.672026-08-05
1 month+0.74%USD 39.152026-07-13
3 month-28.38%USD 55.072026-05-14
Year to date+70.59%USD 23.122025-12-31
1 year+432.97%USD 7.402025-08-12
3 year+338.22%USD 9.002023-08-11
5 year+205.74%USD 12.902021-08-13
Since inception+128.03%USD 16.982020-12-11

Nanobiotix Financials at a Glance

Market Cap

$1.96BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

€22.45M

Net Income (TTM)

-€92.09M

EPS (TTM)

-$0.57

P/E Ratio

-67.72

Dividend

$0.00

Beta (Volatility)

0.88 (Low)

Price

$39.54

Volume

180,530.276

Open

$39.41

Previous Close

$39.44

Daily Range

$38.96 - $40.14

52-Week Range

$7.72 - $57.14

Estimated Earnings Date

Sep 29, 2026

NBTX News

Getty - happy foursome celebrating victory

Biotech Stock Nanobiotix (NBTX) Is Up 660% This Year -- Here's Why the Rally Could Continue

Selena MaranjianNov 24, 2025

NBTX: Motley Fool Moneyball Superscore

59

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Nanobiotix

Nanobiotix S.A. is a clinical-stage biotechnology firm dedicated to developing innovative therapeutic solutions for cancer. The company's flagship experimental drug, NBTXR3, utilizes crystalline hafnium oxide nanoparticles and is being evaluated for various cancer types.

Products and Services
  • NBTXR3, an innovative treatment for multiple cancer types
  • Strategic collaboration with LianBio for Asian market expansion
  • Focus on research and development in oncology
Growth Outlook
  • Recent quarterly revenue reached €3,005,000, indicating market interest
  • Strategic partnerships aim to enhance market penetration in Asia
  • Continued investment in R&D to drive future product development
Financial Highlights
  • Trailing twelve months (TTM) revenue of €26,638,000 reflects growth potential
  • Cash and cash equivalents stood at €52,750,000 as of Q4 2025
  • Operating expenses for Q4 2025 totaled €14,631,000, indicating ongoing investment in R&D
Nanobiotix S.A. operates in the biotechnology sector, focusing on cancer treatment solutions. The company is currently advancing its lead product, NBTXR3, through clinical trials, targeting a wide range of cancers. The strategic collaboration with LianBio is expected to facilitate entry into key Asian markets, enhancing growth prospects. Recent financial data indicates a solid revenue stream and a healthy cash position, which supports ongoing research and development efforts. The company’s commitment to innovation in oncology positions it favorably within the competitive biotechnology landscape.
AI Generated • Jul 24, 2026

Industry

Biotechnology

Sector

Health Care

Employees

97

CEO

Laurent Lévy, PhD

Website

www.nanobiotix.com

Headquarters

Paris, IF 75012, FR

NBTX Financials

Key Financial Metrics (TTM)

Gross Margin

100.00%

Operating Margin

-36.49%

Net Income Margin

-80.83%

Return on Equity

31.23%

Return on Capital

-99.83%

Return on Assets

-35.36%

Earnings Yield

-1.48%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.96BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

50.60M

Volume

180.53K

Avg. Volume

97.31K

Financials (TTM)

Gross Profit

€22.45M

Operating Income

-€79.21M

EBITDA

-€79.22M

Operating Cash Flow

-€52.97M

Capital Expenditure

-€1.39M

Free Cash Flow

-€54.37M

Cash & ST Invst.

€52.75M

Total Debt

€95.32M

Nanobiotix Performance Analysis

Nanobiotix annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31EUR 0N/A
20232023-12-31EUR 32,496,173N/A
20242024-12-31EUR -12,557,348N/A
20252025-12-31EUR 33,454,436N/A
Nanobiotix sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-30-71.8%
Q42024-12-31-277.4%
Q22025-06-30261.6%
Q42025-12-31-88.7%
Nanobiotix annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31EUR -1.727.5%
20232023-12-31EUR -1.16-32.4%
20242024-12-31EUR -1.5634.1%
20252025-12-31EUR -0.57-63.7%
Nanobiotix sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-30-48.4%
Q42024-12-31-113.0%
Q22025-06-3088.8%
Q42025-12-31-254.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

€3.01M

-90.9%

Gross Profit

€3.01M

-90.9%

Gross Margin

100.00%

N/A

Market Cap

$1.96BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$20.20M

N/A

Employees

97

N/A

Net Income

-€18.58M

-60.1%

EBITDA

-€13.16M

-788.6%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

€52.75M

-29.9%

Total Debt

€95.32M

+88.5%

Accounts Receivable

€7.68M

-19.1%

Inventory

€0.00

N/A

Long Term Debt

€91.01M

+99.8%

Short Term Debt

€4.31M

-14.2%

Return on Assets

-35.36%

N/A

Return on Invested Capital

-1.06%

N/A

Free Cash Flow

-€16.41M

-442.2%

Operating Cash Flow

-€16.01M

-433.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
GHRSGH Research PLC
$30.24+3.99%
TYRATyra Biosciences, Inc.
$25.30+0.48%
SVRASavara Inc.
$5.70+2.33%
EYPTEyePoint Pharmaceuticals, Inc.
$13.53+3.68%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$146.15+0.10%
SMCISuper Micro Computer
$37.61+0.19%
INTCIntel
$100.95+0.03%
NOKNokia
$10.32+0.09%

Questions About NBTX

What is the current price of Nanobiotix?

Nanobiotix is trading at $39.44 per share.

What is the 52-week range for Nanobiotix?

Over the past 52 weeks, Nanobiotix has traded between $7.72 and $57.14.

How much debt does Nanobiotix have?

As of the most recent reporting period, Nanobiotix reported total debt of €111.95M.

How much cash does Nanobiotix have on hand?

Nanobiotix reported €61.95M in cash and cash equivalents in its most recent financial results.

What is Nanobiotix’s dividend yield?

Nanobiotix does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services